Navigation Links
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Date:11/6/2008

SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary syndrome (ACS) and carotid endarterectomy (CEA) trials presented at the American Heart Association (AHA) Scientific Sessions 2008 on Sunday, November 9. The conference call and webcast will take place on Monday, November 10, at 8:30 a.m. ET (7:30 a.m. CT).

To participate in the conference call, please dial 888-684-1280 for domestic callers and 913-312-0952 for international callers. A telephone replay of the conference call will be available through Friday, November 14, 2008. To access the replay, please dial 888-203-1112 for domestic callers and 719-457-0820 for international callers and reference conference replay passcode 1268443.

In addition, interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay of the presentation will be archived on the VIA website for 30 days following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. Raptor Pharmaceuticals Provides Update on Targeting Platforms
3. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
4. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
7. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
8. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
11. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... PARIS, November 6 , - ...Linezolid for the,Treatment of Multi-Resistant Sta...vexel, a speciality pharmaceutical company focused...tics designed to overcome the significant global,p...at its most advanced oral,antibacterial NXL103 (fl...
(Date:11/5/2009)...OINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCal...PT ), a specialty pharmaceutical company focused o...tary products that address important therapeutic n... it will host a webcast and teleconference with ma...esults on Thursday, November 12, 2009, at 5:00 p.m...
(Date:11/5/2009)...ULLERTON, Calif., Nov. 5 Renee Cob...ate professor of dermatology at the University of ...nts are experiencing tremendous results with Therm...ed for skin tightening and contouring, features a ...efficacy and improves patient comfort. ,, "The...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2What are the most effective ways of promoting physical exercise in adults 3F 51564 1What are the most effective ways of promoting physical exercise in adults 3F 51564 2What are the most effective ways of promoting physical exercise in adults 3F 51564 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 1Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 2Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 4Pelosi Statement on Appointment of Dr Regina Benjamin as Surgeon General of the United States 51560 1
...or Cancer Research meeting indicate that technolo...-water-soluble drugs to treat cancer and possibly ...r Pharmaceuticals today,reported results on a nove...pable of dissolving in water (hydrophobic drugs) i...ation. These findings allow the company to,combine...
...MOND, Va., April 16 Insmed Inc. (Nasdaq:,INSM), a...ticals, today,announced that it has received appro...care products Regulatory Agency (MHRA) to initiate...n biologic (FOB) product candidate.,Insmed,s INS-1...a follow-on,biologic of the FDA-approved product N...
Other Medicine Technology:Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 2Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 2Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 4
(Date:11/7/2009)...GTON, Nov. 7 The U.S. b...presentatives to vote for the Stupak-Ellsworth Ame...k-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith...on abortion funding and conscience protections in ...962)," they said. ,, The letter was signed by C...
(Date:11/7/2009)...Nov. 7 Americans United for Life Action endorses ...Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith A...ey from going to abortion in health care reform. ,... CEO Dr. Charmaine Yoest said, "Americans United f...rth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendme...
(Date:11/7/2009)... not assume that all youth will rebel, expert says...Teens are more likely to behave badly if their par... "Parents who believe they are simply being realis... prophecy," Christy Buchanan, a psychology profess...study, said in a university news release. "Negativ...
(Date:11/7/2009)... October 23-25th marked the 12th annua...ties fighting the battle against pediatric cancer....ion and it,s efforts for many years. , ...r 7, 2009 -- The weekend of October 23-25 marked ...rs and celebrities fighting the battle against ped...
(Date:11/7/2009)... Forget ‘sweatox’ or &lsqu...is the usage of the anti-ageing jab ‘Breasto...cted into the décolletage, can reduce the a...st area around the breasts, leaving smoother, youn...B) November 7, 2009 -- Transform, the UK’s l...
Breaking Medicine News(10 mins):Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:UK Boobs Get a Boost with 'Breastox' 2
...Ohio, Jan. 30 Cardinal Health Chief,Executive Off...erbeck, will,address investors at the Merrill Lync... Device Conference in New York on Feb. 7 at 9:20 a...ntinued growth. His,remarks will be webcast live. ...
...TI, Jan. 30 , CALL DATE: Wednesday, F...tern Time HOST: Dr. Candace Kend... conduct a telephone conference call and,simultane...wer session will follow., (Logo: http://www.news...
...ealthcare to Offer Unique and Cost-Effective Appro... Clinical Outcomes, TORONTO and PHOENIX, Jan. 30 ...ns and health information solution provider,based ...n Phoenix, Arizona, to provide its innovative inte...
...Mich., Jan. 30 The Michigan Business and,Professi...ociation Michigan,Food and Beverage Association (M...at employ over 180,000 individuals throughout the ... Senate,approval. "With today,s economy in mind, w...
...nt and Vestar Capital Partners Purchase Interest f...al Partners, SOUTH BEND, Ind. and NEW YORK, Jan. ...ider of health care performance,improvement soluti...Securities Capital Partners, LLC (ASCP). The,Press...
...CITY, Calif. and FORT LAUDERDALE, Fla., Jan. 30, C...,its innovative C-Port(R) Distal Anastomosis Syste...acic surgeons at the 2008 STS University. In,addit...eting of The Society of Thoracic Surgeons (STS) in...
Other Medicine News:Health News:Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynch's Global Pharmaceutical, Biotechnology and Medical Device Conference 2Health News:Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 2Health News:Life:WIRE(TM) to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 2Health News:Individual Healthcare Reform Necessity in New Business Economy 2Health News:Press Ganey Takes on New Investment Partner 2Health News:Press Ganey Takes on New Investment Partner 3Health News:Press Ganey Takes on New Investment Partner 4Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 2Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 3
Cruchfield Skull Traction Tong
...ll base surgery. Complete implant selection for: c... pediatric neurosurgery, bony defects of the masto...o trauma. Dedicated neuro/skull base system combin...RI and CT compatible implants. Available with the ...
Crutchfield Skull Traction Tong
Ralk Hand Drill
Medicine Products: